According to a study published in "Journal Of Pharmaceutical Negative Results", dialysis-dependent chronic hepatitis C patients treated with Sofosbuvir + Daclatasvir had greater treatment effectiveness at 3 and 6 months of treatment as opposed to those treated with Sofosbuvir alone. For hepatitis C virus (HCV) management, researchers compared the effectiveness of Sofosbuvir + Daclatasvir versus Sofosbuvir alone.

Treatment naïve patients of either gender (n = 108) receiving hemodialysis and suffering from HCV were included in this randomized controlled trial. All the volunteers had HCV RNA levels ≥100,000 IU/mL and ranged in age from 18 to 65 years. By using the lottery approach, all of the recruited candidates were randomized into 2 groups. In the dialysis department, people in Group A received Sofosbuvir and Daclatasvir together, whereas those in Group B received Sofosbuvir alone.

Viral load estimated at three months and sustained virological response at six months were used to assess the study's results. Group A had 50.0% of men (n=27/54) and 50.0% of females (n=27/54) whereas group B contained 53.7% of males (n=29/54) and 46.3% of females (n=25/54).

Subjects in group A had a mean age of 42.8 years ± 12.1 standard deviation (SD), whereas those in group B had a mean age of 47.2 years ± 10.7 SD. The mean duration of dialysis was 24.3 years ± 17.3 SD for group B candidates and 28.3 months ± 25.7 SD for group A volunteers.

In group A, 7.4% (n=4/54) had no baseline comorbidity, 5.6% (n=3/54) exhibited hypertension, 55.6% (n=30/54) suffered from diabetes, 1.9% (n=1/54) had ischemic heart disease, and 29.6% (n=16/54) had multiple comorbidities at the baseline. In group B, the percentages were as follows: 14.8% (n=8/54), 1.9% (n=1/54), 53.7% (n=19/54), 1.9% (n=1/54), and 27.8% (n=15/54). Notably, 98.1% (n=53/54) of subjects in group A and 96.3% (n=52/54) of patients in group B did not have viral load three months after the commencement of the therapy.

Sustained virological response was attained in 98.1% (n=53/54) of subjects in group A and 96.3% (n=52/54) of subjects in group B six months after the commencement of therapy. For the treatment of HCV infection, combination therapy with Sofosbuvir and Daclatasvir was superior to monotherapy with Sofosbuvir at 3 and 6 months. However, there was no clinically meaningful difference.